Lartesertib - Merck KGaA
Alternative Names: M-4076Latest Information Update: 28 Jun 2024
At a glance
- Originator Merck KGaA
- Class Antineoplastics; Radiation-sensitising agents
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in Canada (PO, Tablet)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in USA (PO, Tablet)
- 03 Jun 2024 EMD Serono plans a phase II DDRiver EOC 302 trial for Ovarian cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA and Germany (PO) (NCT06433219)